For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG GY018

Trial Overview

Official Title

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Endometrial Cancer.

Study Purpose

The purpose of this study is to compare any good and bad effects of adding immunotherapy drugs to the usual combination of chemotherapy drugs.

Diagnosis

Patient has endometrial cancer and your tumor has been tested for mismatch repair (MMR) deficiency.

Eligibility

Measurable Stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.

No prior chemotherapy or was completed >12 months and must be registered to the study within 12 months of diagnosis.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Treated with a placebo, paclitaxel and carboplatin. 
  • Group 2: Treated with a study drug called pembrolizumab, paclitaxel and carboplatin. 

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
GY018